within Pharmacolibrary.Drugs.J_AntiinfectivesForSystemicUse.J05A_DirectActingAntivirals.J05AD01_Foscarnet;

model Foscarnet
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C(
    weight = 70,
    F = 1,
    Cl = 8.75e-06,
    adminDuration = 600,
    adminMass = 60 / 1000000,
    adminCount = 1,
    Vd = 0.00032,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    Vdp = 0.00019,
    k12 = 4.783333333333333e-06,
    k21 = 4.783333333333333e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Foscarnet</td></tr><tr><td>ATC code:</td><td>J05AD01</td></tr><td>route:</td><td>intravenous</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>60</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>0.32</td><td>L</td></tr>
    <tr><td>clearance:</td><td>7.5</td><td>mL/min/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Foscarnet is an antiviral drug that acts as a pyrophosphate analog, inhibiting viral DNA polymerases and reverse transcriptases. It is mainly used for the treatment of cytomegalovirus (CMV) retinitis in patients with AIDS and for acyclovir-resistant herpes simplex virus (HSV) infections. Foscarnet is approved for medical use in the United States and other countries for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported in adult HIV-positive patients with normal renal function after intravenous infusion.</p><h4>References</h4><ol><li><p>Marshall, BC, &amp; Koch, WC (2009). Antivirals for cytomegalovirus infection in neonates and infants: focus on pharmacokinetics, formulations, dosing, and adverse events. <i>Paediatric drugs</i> 11(5) 309–321. DOI:<a href=\"https://doi.org/10.2165/11316080-000000000-00000\">10.2165/11316080-000000000-00000</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/19725597/\">https://pubmed.ncbi.nlm.nih.gov/19725597</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.J.J05AD01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Foscarnet;
